You are here: Industry Insights > Lundbeck

News List

Ranbaxy, Lundbeck face EU fury for blocking generics biospectrumasia
October 12, 2018
Ranbaxy, Lundbeck face EU fury for blocking generics
After seeing POC data, Kyowa advances Parkinson’s program despite being dropped by Lundbeck fiercebiotech
August 21, 2018
Kyowa Hakko Kirin has posted (PDF) a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients. The data emboldened Kyowa to commit to a larger phase 2 trial, despite its one-time partner Lundbeck wal
Lundbeck snaps up Parkinson’s candidate via Prexton buy pharmatimes
July 23, 2018
Lundbeck has announced plans to buy Prexton Therapeutics in a deal valued at up to 905 million euros.
Lundbeck takes risk on Parkinson’s treatment, €905m on table pharmafile
March 20, 2018
CNS’ treatments are notoriously risky, especially those that are still at an early stage; however, Lundbeck has decided to take a calculated risk on Prexton Therapeutics and its sole candidate for Parkinson’s.
Lundbeck Acquires Prexton Therapeutics biospace
March 19, 2018
Denmark-based H. Lundbeck A/S dropped €100 million in upfront money, or about $123 million, to acquire Prexton Therapeutics, a 2012 spinout from Merck KGaA, and its Phase II treatment for Parkinson’s disease.
Lundbeck partners with Vanderbilt University on schizophrenia research project pharmafile
January 11, 2018
Danish pharmaceutical firm Lundbeck has signed a separate licensing and research collaboration agreement with Tennessee’s Vanderbilt University to develop a novel solution in the treatment of schizophrenia, it has emerged.
Lundbeck trial investigates genetic causes of depression pharmaphorum
August 03, 2017
Danish pharma Lundbeck has joined personal genetics company 23andMe and think tank the Milken Institute in a large new study to increase the understanding of the underlying causes of depression.
Lundbeck continues to show solid revenue growth and strong improvement in profitability firstwordpharma
February 09, 2017
Revenue reached DKK 15,634 million in 2016 representing an increase of 7% compared to last year.

Previous page 1 2 Next page